Avantika Ghosh

Avantika Ghosh

Auto-generated profile, based on publicly available information

Avantika Ghosh

Division of Cancer Research, Department of Thoracic Surgery, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CTCarla Tangermann
Carla Tangermann
AGAvantika Ghosh
Avantika Ghosh
MZMartin Ziegler
Martin Ziegler
FFFrancesco Facchinetti
Francesco Facchinetti
JSJannis Stappenbeck
Jannis Stappenbeck
SDSven Diederichs
Sven Diederichs
Variants of uncertain significance represent the biggest challenge for genomics-based precision oncology. Activated fibroblast growth factor receptors (FGFRs) frequently drive tumorigenesis by different genetic aberrations. However, it remains unknown which of the many point mutations affecting FGFR1 , FGFR2 , FGFR3 or FGFR4 in cancer are druggable, that is, activating signaling while not mediating FGFR inhibitor resistance. Here we implemented a saturation mutational scanning platform to screen all 11,520 possible point mutations covering the kinase domains of FGFR1 – 4 . Pooled positive selection screens identified 474 activating and 738 mutations mediating resistance to the FGFR inhibitors pemigatinib and futibatinib, together revealing 301 druggable FGFR mutations analogous to a strong PS3/BS3 evidence level. The screens also identified loss-of-function mutations and an association of gain-of-function mutations with hydrophobic changes. The functional screens identified 97% of acquired resistance mutations in clinical trials. Our comprehensive catalog of every druggable mutation in the FGFR kinase domains is readily available for clinical decision support.

14 February 2025 in Science Advances
Verified
Journal Article
Open access
JPJagriti Pal
Jagriti Pal
MRMarisa Riester
Marisa Riester
AGAthina Ganner
Athina Ganner
AGAvantika Ghosh
Avantika Ghosh
SDsonam Dhamija
sonam Dhamija
SDSven Diederichs
Sven Diederichs
Nonstop extension or stop-loss mutations lead to the extension of a protein at its carboxyl terminus. Recently, nonstop mutations in the tumor suppressor SMAD Family Member 4 ( SMAD4 ) have been discovered to lead to proteasomal SMAD4 degradation. However, this mutation type has not been studied in other cancer genes. Here, we explore somatic nonstop mutations in the tumor suppressor genes BRCA1 Associated Protein 1 ( BAP1 ) and Von Hippel-Lindau ( VHL ) enriched in renal cell carcinoma. For BAP1 , nonstop mutations generate an extremely long extension. Instead of proteasomal degradation, the extension decreases translation and depletes BAP1 messenger RNA from heavy polysomes. For VHL , the short extension leads to proteasomal degradation. Unexpectedly, the mutation alters the selection of the translational start site shifting VHL isoforms. We identify germline VHL nonstop mutations in patients leading to the early onset of severe disease manifestations. In summary, nonstop extension mutations inhibit the expression of renal tumor suppressor genes with pleiotropic effects on translation and protein stability.